Check out what we’ve been up to and where can we connect!
September 21, 2021
The results from this study provide important information about the clinical management of hospitalized patients with COVID-19. Additional research is needed to identify a method that can be used to accurately prioritize patients with COVID-19 at risk of critical illness or death.
June 23, 2021
Tiziana and FHI Clinical announce collaboration on a Phase 2 study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe COVID-19 and pulmonary inflammation.
April 24, 2021
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
March 29, 2021
Phase I/II studies to evaluate human placental hematopoietic stem cell–derived natural killer (NK) cell therapy to treat COVID-19 in hospitalized adults are currently ongoing as part of our partnership with the Infectious Disease Research Institute (IDRI).
April 12, 2022
Join us for an episode of Careers in Pharma, a webinar featuring Daniel Joffe, Senior Clinical Project Manager at FHI Clinical, as he talks about his role as a project manager, challenges he faces and skills he uses.
March 17-19, 2022
At the 5th annual WAC-CREP conference, FHI Clinical employees are presenting findings from research being conducted within the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network.
February 22, 2022
Join us for this plenary discussion in which experts in infectious diseases discuss how real-world epidemiology data, site capacity data and biosurveillance methodology could help identify TB-prevalent populations during protocol design, helping to ensure an adequate sample for TB vaccine development.
February 22-25, 2022
Attending the Global Forum on TB Vaccines? Visit our booth to learn more about our services or schedule a meeting with our team.
February 7-10, 2022
Attending SCOPE? Learn more about how we ensure best-fit sites with the most appropriate capabilities and patient populations tailored to your study protocol. Contact us to set aside time to review your feasibility and study start-up needs.
November 30 – December 2, 2021
Attending the World Vaccine and Immunotherapy Congress West Coast? Schedule a meeting with an FHI Clinical team member who will be in attendance at the event.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA